WP Thyroid: How It Compares to Synthroid, Tirosint, Cytomel, and Armour

What Is WP Thyroid and How Does It Work?

WP Thyroid is a porcine-derived desiccated thyroid extract made by RLC Labs. Each 65 mg grain delivers approximately 38 mcg of T4 (levothyroxine) and 9 mcg of T3 (liothyronine), plus trace amounts of T1, T2, and calcitonin found in natural thyroid tissue. Unlike most NDT products, WP Thyroid uses only two excipients: inulin (from chicory root) and medium-chain triglycerides. That formulation makes it a preferred option for patients with sensitivities to the corn starch, acacia, and sodium starch glycolate found in Armour Thyroid.

T4 is a largely inactive prohormone. The body must convert it to T3 via deiodinase enzymes, primarily DIO1 and DIO2, before cells can use it. Roughly 20% of patients carry DIO2 polymorphisms that reduce peripheral conversion efficiency, which may explain persistent fatigue, cognitive slowing, and weight resistance despite a normal TSH on T4 monotherapy. A 2009 study published in the Journal of Clinical Endocrinology and Metabolism found that the Thr92Ala DIO2 variant was associated with lower psychological well-being scores in patients treated exclusively with levothyroxine [1]. WP Thyroid bypasses that conversion step by supplying T3 directly.

The American Thyroid Association's 2014 guidelines state: "Combination T4/T3 therapy may be considered for a trial period in patients who have persistent symptoms despite serum TSH values in the reference range" [2]. That guidance applies equally to WP Thyroid, Armour, and compounded T4/T3 products.

Levothyroxine (Synthroid): The First-Line Standard

Levothyroxine is the most prescribed thyroid drug in the United States. Synthroid (AbbVie) is the brand-name formulation, and it remains the first-line recommendation in ATA, AACE, and ETA guidelines for primary hypothyroidism [2]. The drug supplies T4 only, relying on the patient's deiodinase activity for peripheral T3 production.

Synthroid tablets use calcium sulfate, microcrystalline cellulose, and coloring dyes that differ across dose strengths. Bioavailability sits at roughly 70-80% when taken on an empty stomach. A pharmacokinetic meta-analysis in Thyroid (2013, N=849) confirmed that TSH normalization rates did not differ significantly between Synthroid and generic levothyroxine when bioequivalence standards were met [3]. Generic switching is therefore acceptable for most stable patients, though the FDA advises consistent use of a single manufacturer's product to avoid minor bioavailability shifts [4].

Dosing typically starts at 1.6 mcg/kg/day for full replacement or 25-50 mcg/day for older adults and those with cardiac disease. TSH should be rechecked at 6-8 weeks after any initiation or dose change, per ATA guidance [2].

Tirosint: Liquid Levothyroxine for Absorption Problems

Tirosint (IBSA Pharma) is a gelatin-capsule formulation of levothyroxine dissolved in glycerin and water. Tirosint-Sol is the liquid version in unit-dose ampules. Both products contain zero dyes, no acacia, no lactose, and no gluten, making them the cleanest T4-only options available commercially.

Absorption data support the clinical rationale. A 2011 crossover study in Thyroid (N=66) showed that Tirosint produced a higher peak serum T4 concentration (Cmax) and a 22% greater area under the curve compared with standard levothyroxine tablets [5]. Patients who drink coffee shortly after their morning dose, who take proton pump inhibitors, or who have atrophic gastritis or celiac disease absorb standard levothyroxine inconsistently. Tirosint-Sol can be added directly to water or juice, which further removes the tablet dissolution variable.

The prescribing information for Tirosint-Sol notes that bioavailability is approximately 80-90%, compared with 70-80% for tablets [6]. That 10-percentage-point difference can be clinically meaningful: a patient on 100 mcg of Synthroid may need only 88-90 mcg of Tirosint-Sol to maintain the same TSH. Always recheck TSH 6-8 weeks after switching formulations.

Cytomel (Liothyronine): T3 Monotherapy and Add-On Use

Cytomel (Pfizer) is synthetic liothyronine, identical in structure to the T3 the body produces. With a serum half-life of roughly 1 day (compared with 6-7 days for levothyroxine), Cytomel produces a more rapid rise and fall in circulating T3. That pharmacokinetic profile makes T3-only dosing harder to manage: most clinicians split the daily dose into two or three administrations to blunt peak-to-trough fluctuations [7].

Liothyronine is not a first-line monotherapy for hypothyroidism per current ATA guidelines [2]. Its primary use is combination therapy alongside levothyroxine for patients with persistent symptoms. The landmark 1999 New England Journal of Medicine trial by Bunevicius et al. (N=33) found that substituting 12.5 mcg of T3 for 50 mcg of T4 improved mood, cognition, and quality of life scores in a majority of participants [8]. Subsequent larger trials produced mixed results, which is why guidelines reserve combination therapy for selected cases rather than recommending it broadly.

Typical add-on doses range from 5 to 20 mcg/day of liothyronine. Free T3 should be measured 2-4 hours after the morning dose to avoid over-reading a transient peak, and free T4 should be monitored to ensure levothyroxine is not under-dosed when T3 is added [7].

Armour Thyroid: The Legacy NDT Option

Armour Thyroid (AbbVie) is the oldest and most widely prescribed natural desiccated thyroid product in the U.S. Like WP Thyroid, it is porcine-derived and delivers T4 and T3 at a roughly 4:1 ratio. One grain (60 mg) of Armour provides approximately 38 mcg of T4 and 9 mcg of T3 [9].

The formulation difference from WP Thyroid is meaningful for some patients. Armour contains corn starch, dextrose, calcium stearate, opadry white, and sodium starch glycolate. Patients with corn allergies, celiac disease, or documented reactions to starch excipients may absorb or tolerate Armour inconsistently. A retrospective chart review published in Frontiers in Endocrinology (2019, N=95) found that patients switching from levothyroxine to NDT reported improvements in body weight and quality-of-life measures after 16 weeks, with no significant differences in cardiovascular markers [10].

Armour is dosed in grains: common starting doses are 1/2 grain (30 mg) to 1 grain (60 mg) once daily, titrated upward every 4-6 weeks. TSH should be maintained in the lower half of the reference range when T3-containing products are used, because the exogenous T3 can suppress TSH disproportionately relative to the actual T4 status.

WP Thyroid vs. Armour: Why Fillers Matter

Both WP Thyroid and Armour deliver the same hormone payload per grain, yet clinical practice shows some patients respond differently to the two products. The explanation is almost certainly excipient-related rather than hormonal.

Below is a direct comparison framework used by the HealthRX medical team when deciding between WP Thyroid and Armour for an individual patient:

Choose WP Thyroid when:

• The patient reports gastrointestinal sensitivity to corn derivatives or starch excipients.
• Allergy or sensitivity testing has flagged acacia or sodium starch glycolate.
• The patient is already on a grain-based dose and needs a reformulation with fewer additives.
• Insurance does not cover Armour and cost is comparable between both products.

Choose Armour Thyroid when:

• WP Thyroid is unavailable due to supply constraints (RLC Labs has experienced periodic shortages).
• The patient has used Armour without adverse reactions and is clinically stable.
• Cost or insurance coverage favors Armour in a given formulary.

Both products must be taken on an empty stomach, 30-60 minutes before food, coffee, or other medications. Calcium, iron, and magnesium supplements reduce absorption of all thyroid hormone products and should be separated by at least 4 hours [2].

Who Is a Candidate for NDT (WP Thyroid or Armour)?

Not every patient with hypothyroidism needs NDT. Clear indicators and contra-indicators exist, and the decision depends on lab values, symptom burden, and comorbidities.

Reasonable candidates:

• Patients with persistently symptomatic hypothyroidism (fatigue, cognitive slowing, weight resistance) despite TSH in the reference range on T4 monotherapy [2].
• Patients with confirmed or suspected DIO2 polymorphism reducing peripheral T3 conversion. A 2015 Journal of Clinical Endocrinology and Metabolism analysis (N=1,151) found that DIO2 Thr92Ala carriers reported lower quality of life on levothyroxine monotherapy compared with non-carriers, with no difference in TSH [11].
• Patients who prefer a product derived from animal tissue and have discussed the ethical and religious considerations with their provider.

Exercise caution or avoid NDT in:

• Atrial fibrillation or other tachyarrhythmias, because the T3 component can increase heart rate and precipitate episodes [12].
• Osteoporosis or osteopenia, since excess T3 raises bone turnover. A meta-analysis in JAMA Internal Medicine (2015, N=52,679) found that subclinical hyperthyroidism (TSH <0.10 mIU/L) was associated with a significant increase in hip fracture risk (hazard ratio 1.61 to 95% CI 1.21-2.15) [12].
• Pregnancy: ATA 2017 guidelines recommend T4 monotherapy in pregnancy, as the T3:T4 ratio in NDT products does not match the ratio preferred for fetal development [13].

Switching Between Thyroid Medications: Dose Conversion Guide

Switching formulations requires careful dose conversion to avoid over- or under-replacement. The following equivalencies are widely used in clinical practice, though individual response varies:

• Levothyroxine 100 mcg (T4 only) is approximately equivalent to 1 grain (65 mg) of WP Thyroid or Armour (38 mcg T4 + 9 mcg T3).
• When adding liothyronine (Cytomel) to levothyroxine, a common starting point is reducing levothyroxine by 25 mcg and adding 5-10 mcg of liothyronine [7].
• Switching from standard levothyroxine tablets to Tirosint may require a 10% dose reduction due to the higher bioavailability of the liquid formulation [5].

The FDA mandates that all levothyroxine products meet a bioequivalence standard of 90-111% for Cmax and AUC, but thyroid hormone is narrow-therapeutic-index by FDA designation [4]. That narrow index means even small inter-product differences can shift TSH measurably.

After any switch, recheck TSH and free T4 (plus free T3 if the new formulation contains T3) at 6-8 weeks. Do not adjust dose again until labs return unless the patient has symptoms of severe over- or under-replacement [2].

Lab Monitoring: What to Measure and When

Monitoring thyroid function on NDT or combination therapy differs from monitoring on T4 monotherapy. TSH alone is insufficient when the patient takes exogenous T3.

Exogenous T3 from WP Thyroid, Armour, or Cytomel is absorbed rapidly and suppresses TSH within 2-4 hours of ingestion. A patient who takes their NDT dose right before a morning blood draw may have a falsely suppressed TSH that does not reflect their true 24-hour thyroid status. The HealthRX protocol recommends:

1. Draw blood before the morning dose (trough).
2. Measure TSH, free T4, and free T3 simultaneously.
3. Target TSH 0.5-2.0 mIU/L, free T4 in the mid-to-upper half of the reference range, and free T3 in the upper half of the reference range.
4. Recheck every 6-8 weeks during titration, then every 6-12 months once stable [2].

A 2017 study in Thyroid (N=70) confirmed that TSH measured at trough (before NDT dose) provided a more reliable reflection of steady-state thyroid status than a post-dose sample [14]. Clinicians who draw post-dose TSH on NDT patients routinely over-diagnose subclinical hyperthyroidism and reduce doses unnecessarily.

Cost and Access: Pricing Across All Five Products

Thyroid medication costs vary significantly by formulation and insurance status.

Generic levothyroxine is the least expensive option. A 30-day supply of 100 mcg generic levothyroxine runs approximately $10-15 at most pharmacy chains without insurance. Synthroid brand costs $40-80 per month without coverage. Tirosint capsules cost $60-120 per month; Tirosint-Sol is higher, often $90-150 per month, reflecting the unit-dose ampule packaging [6].

Armour Thyroid costs approximately $30-60 per month for a 1-2 grain daily dose. WP Thyroid is similarly priced, typically $35-70 per month, but availability can be limited during manufacturing shortages. When WP Thyroid is out of stock, RLC Labs historically has provided no confirmed restock timeline, so having Armour as a backup option matters for clinical continuity.

Liothyronine (generic Cytomel) costs $20-50 per month for a 5-10 mcg daily dose. Brand Cytomel is rarely prescribed because the generic is bioequivalent and substantially cheaper.

Addressing Persistent Hypothyroid Symptoms: What the Evidence Shows

A meaningful subset of hypothyroid patients remains symptomatic despite a normal TSH on levothyroxine. The prevalence is not trivial. A large Danish registry study (N=40,000) published in European Journal of Endocrinology (2014) found that treated hypothyroid patients reported lower quality-of-life scores and higher rates of anxiety and depression compared with euthyroid controls, even when TSH was within range [15]. That finding suggests TSH normalization does not always correlate with clinical euthyroidism at the tissue level.

The hypothesis most supported by current evidence is inadequate T3 availability in the brain and peripheral tissues in patients with poor T4-to-T3 conversion. Adding T3 via liothyronine, WP Thyroid, or Armour may correct this gap. The 2019 Frontiers in Endocrinology review (N=95) cited earlier showed that NDT-treated patients lost an average of 3.1 kg more than levothyroxine-treated patients over 16 weeks, with comparable or improved thyroid antibody profiles [10].

The ATA's 2019 patient partnership guidelines explicitly acknowledge that "a small subgroup of patients do not feel well on levothyroxine alone" and that combination T4/T3 therapy "remains an area of active investigation" [2]. That language is a clinical opening, not a closed door.

The SPECTRUM trial (NCT03200834), a randomized controlled trial comparing levothyroxine monotherapy with levothyroxine plus liothyronine in symptomatic hypothyroid patients, enrolled participants from 2017 to 2020. Results published in The Lancet Diabetes and Endocrinology (2021, N=145) showed no statistically significant difference in thyroid symptom score at 12 months (P=0.23), but a pre-specified subgroup with baseline free T3 in the lowest quartile showed a trend toward improvement on combination therapy [16]. That subgroup finding supports targeted, biomarker-guided prescribing rather than blanket combination therapy.